Safety evaluation of the food enzyme triacylglycerol lipase from the genetically modified Aspergillus oryzae strain NZYM‐PH Authors: EFSA Panel on Food Enzymes (FEZ), Holger Zorn, José Manuel Barat Baviera, Claudia Bolognesi, Francesco Catania, Gabriele Gadermaier, Ralf Greiner, Baltasar Mayo, Alicja Mortensen, Yrjö Henrik Roos, Marize de Lourdes Marzo Solano, Henk Van Loveren, Laurence Vernis, Jaime Aguilera, Magdalena Andryszkiewicz, Daniele Cavanna, Natalia Kovalkovicova, Yi Liu Published: 2025 ABSTRACT AbstractThe food enzyme triacylglycerol lipase (triacylglycerol acylhydrolase; EC 3.1.1.3) is produced with the genetically modified Aspergillus oryzae NZYM‐PH strain by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme was considered free from viable cells of the production organism and its DNA. It is intended to be used in six food manufacturing processes. Dietary exposure was estimated to be up to 0.226 mg total organic solids (TOS)/kg body weight (bw) per day in European populations. Genotoxicity tests did not indicate a safety concern. The systemic toxicity was assessed by means of a repeated dose 90‐day oral toxicity study in rats. The Panel identified a no observed adverse effect level of 1283 mg TOS/kg bw per day, the highest dose tested, which when compared with the estimated dietary exposure, resulted in a margin of exposure of at least 5677. A search for the homology of the amino acid sequence of the triacylglycerol lipase to known allergens was made and no match was found. The Panel considered that a risk of allergic reactions upon dietary exposure to the food enzyme cannot be excluded, but that the likelihood is low. Based on the data provided, the Panel concluded that this food enzyme does not give rise to safety concerns, under the intended conditions of use. INTRODUCTION Article 3 of the Regulation (EC) No 1332/2008 1 provides definition for ‘food enzyme’ and ‘food enzyme preparation’. ‘Food enzyme’ means a product obtained from plants, animals or microorganisms or products thereof including a product obtained by a fermentation process using microorganisms: (i) containing one or more enzymes capable of catalysing a specific biochemical reaction; and (ii) added to food for a technological purpose at any stage of the manufacturing, processing, preparation, treatment, packaging, transport or storage of foods. ‘Food enzyme preparation’ means a formulation consisting of one or more food enzymes in which substances such as food additives and/or other food ingredients are incorporated to facilitate their storage, sale, standardisation, dilution or dissolution. Before January 2009, food enzymes other than those used as food additives were not regulated or were regulated as processing aids under the legislation of the Member States. On 20 January 2009, Regulation (EC) No 1332/2008 on food enzymes came into force. This Regulation applies to enzymes that are added to food to perform a technological function in the manufacture, processing, preparation, treatment, packaging, transport or storage of such food, including enzymes used as processing aids. Regulation (EC) No 1331/2008 2 established the European Union (EU) procedures for the safety assessment and the authorisation procedure of food additives, food enzymes and food flavourings. The use of a food enzyme shall be authorised only if it is demonstrated that: it does not pose a safety concern to the health of the consumer at the level of use proposed;there is a reasonable technological need;its use does not mislead the consumer. it does not pose a safety concern to the health of the consumer at the level of use proposed; it does not pose a safety concern to the health of the consumer at the level of use proposed; there is a reasonable technological need; there is a reasonable technological need; its use does not mislead the consumer. its use does not mislead the consumer. All food enzymes currently on the EU market and intended to remain on that market, as well as all new food enzymes, shall be subjected to a safety evaluation by the European Food Safety Authority (EFSA) and approval via an EU Community list. Background and Terms of Reference as provided by the requestor Background as provided by the European Commission Only food enzymes included in the Union list may be placed on the market as such and used in foods, in accordance with the specifications and conditions of use provided for in Article 7(2) of Regulation (EC) No 1332/2008 on food enzymes. Five applications have been introduced by the companies “Erbsloh Geisenheim AG” for the authorisation of the food enzyme Endo‐1,3(4)‐beta‐glucanase from Talaromyces versatilis (strain PF8), “Novozymes A/S" for the authorisation of the food enzyme Lipase from a genetically modified strain of Aspergillus oryzae (strain NZYM‐PH), and “Danisco US Inc.” for the authorisation of the food enzymes 4‐Phytase from a genetically modified strain of Trichoderma reesei (DP‐Nzt55), Alpha‐amylase from a genetically modified strain of Bacillus licheniformis (DP‐Dzb54) and Pullulanase from a genetically modified strain of Bacillus licheniformis (DP‐Dzp39). Following the requirements of Article 12.1 of Regulation (EC) No 234/20113 implementing Regulation (EC) No 1331/2008, the Commission has verified that the five applications fall within the scope of the food enzyme Regulation and contain all the elements required under Chapter II of that Regulation. Terms of Reference The European Commission requests the European Food Safety Authority to carry out the safety assessments on the food enzymes Endo‐1,3(4)‐beta‐glucanase from Talaromyces versatilis (strain PF8), Lipase from a genetically modified strain of Aspergillus oryzae (strain NZYM‐PH), 4‐Phytase from a genetically modified strain of Trichoderma reesei (DP‐Nzt55), Alpha‐amylase from a genetically modified strain of Bacillus licheniformis (DP‐Dzb54) and Pullulanase from a genetically modified strain of Bacillus licheniformis (DP‐Dzp39) in accordance with Article 17.3 of Regulation (EC) No 1332/2008 on food enzymes. Interpretation of the Terms of Reference The present scientific opinion addresses the European Commission's request to carry out the safety assessment of the food enzyme lipase from the genetically modified Aspergillus oryzae strain NZYM‐PH. DATA AND METHODOLOGIES Data The applicant has submitted a dossier in support of the application for authorisation of the food enzyme triacylglycerol lipase from a genetically modified Aspergillus oryzae (strain NZYM‐PH). Additional information, requested from the applicant during the assessment process on 27 March 2023, were received on 26 March 2024 (see ‘Documentation provided to EFSA’). Methodologies The assessment was conducted in line with the principles described in the EFSA ‘Guidance on transparency in the scientific aspects of risk assessment’ (EFSA, 2009a) and following the relevant guidance documents of the EFSA Scientific Committee. The ‘Guidance on the submission of a dossier on food enzymes for safety evaluation’ (EFSA, 2009b) as well as the ‘Statement on characterisation of microorganisms used for the production of food enzymes’ (EFSA CEP Panel, 2019) have been followed for the evaluation of the application. Additional information was requested in accordance with the updated ‘Scientific Guidance for the submission of dossiers on food enzymes’ (EFSA CEP Panel, 2021) and the guidance on the ‘Food manufacturing processes and technical data used in the exposure assessment of food enzymes’ (EFSA CEP Panel, 2023). ASSESSMENT IUBMB nomenclatureTriacylglycerol lipaseSystematic nameTriacylglycerol acylhydrolaseSynonymsLipase; triglyceride lipaseIUBMB NoEC 3.1.1.3CAS No9001‐62‐1EINECS No232‐619‐9 IUBMB nomenclatureTriacylglycerol lipaseSystematic nameTriacylglycerol acylhydrolaseSynonymsLipase; triglyceride lipaseIUBMB NoEC 3.1.1.3CAS No9001‐62‐1EINECS No232‐619‐9 Triacylglycerol lipases catalyse, in the presence of water, the hydrolysis of the ester linkages in triacylglycerols, resulting in the generation of glycerol, free fatty acids, mono‐ and diacylglycerols. The food enzyme under assessment is intended to be used in six food manufacturing processes as defined in the EFSA guidance (EFSA CEP Panel, 2023): (1) processing of dairy products for the production of modified milk proteins; (2) processing of eggs and egg products; processing of cereals and other grains for the production of (3) baked products and (4) cereal‐based products other than baked; processing of plant‐ and fungal‐derived products for the production of (5) plant‐based analogues of milk and milk products and (6) protein hydrolysates. Source of the food enzyme The triacylglycerol lipase is produced with the genetically modified filamentous fungus Aspergillus oryzae strain NZYM‐PH, which is deposited at the German Collection of Microorganisms and Cell Cultures (DSMZ, Germany) with the deposition number ■■■■■. 3 The production strain was identified as A. oryzae by phylogenetic analysis based on the sequences of the ■■■■■. 4 Characteristics of the parental and recipient microorganisms The parental strain is ■■■■■. The recipient strain ■■■■■ 5 was developed from the parental strain ■■■■■ through several genetic modification steps. 6 ■■■■■. 7 In the genetic modification steps, ■■■■■. The absence of the ■■■■■ gene from the recipient strain was verified by Southern blot analysis. 8 Characteristics of introduced sequences ■■■■■ 9 ■■■■■ ■■■■■. 10 Description of the genetic modification process The purpose of genetic modification was to enable the production strain to synthesise triacylglycerol lipase from ■■■■■. 11 ■■■■■. 12 Finally, one mutant that showed increased expression of triacylglycerol lipase, was selected as the production strain NZYM‐PH. 13 The presence of multiple copies of the ■■■■■ into the genome of the production strain was confirmed by real‐time polymerase chain reaction (RT‐PCR) analysis. 14 Safety aspects of the genetic modification The technical dossier contains all necessary information on the recipient microorganism, the donor organism and the genetic modification process. The production strain NZYM‐PH differs from the recipient strain ■■■■■. It also lacks the ■■■■■. The absence of the ■■■■■ gene in the production strain was verified by Southern blot analysis. 15 No issues of concern arising from the genetic modifications were identified by the Panel. Production of the food enzyme The food enzyme is manufactured according to the Food Hygiene Regulation (EC) No 852/2004, 16 with food safety procedures based on Hazard Analysis and Critical Control Points and in accordance with Good Manufacturing Practice. 17 The production strain is grown as a pure culture using a typical industrial medium in a ■■■■■ fermentation system with conventional process controls in place. After completion of the fermentation, the solid biomass is removed from the fermentation broth by filtration. The filtrate containing the enzyme is further purified and concentrated, including an ultrafiltration step in which enzyme protein is retained, while most of the low molecular mass material passes the filtration membrane and is discarded. 18 The applicant provided information on the identity of the substances used to control the fermentation and in the subsequent downstream processing of the food enzyme. 19 The Panel considered that sufficient information has been provided on the manufacturing process and the quality assurance system implemented by the applicant to exclude issues of concern. Characteristics of the food enzyme Properties of the food enzyme The triacylglycerol lipase is a single polypeptide chain of ■■■■■ amino acids. 20 The molecular mass of the mature protein, calculated from the amino acid sequence, is ■■■■■ kDa. 21 The food enzyme was analysed by sodium dodecyl sulfate‐polyacrylamide gel electrophoresis. A consistent protein pattern was observed across all batches. The gel showed a major protein band corresponding to an apparent molecular mass of about ■■■■■ kDa, consistent with the expected mass of the enzyme. 22 The food enzyme was tested for α‐amylase and α‐glucosidase activities. Only α‐glucosidase activity was detected. No other enzyme activities were reported. 23 The applicant's in‐house determination of triacylglycerol lipase activity is based on hydrolysis of tributyrin (reaction conditions: pH 7.0, 30°C, 90 s) and determined by titration of the released butyric acid using sodium hydroxide. The triacylglycerol lipase activity is expressed in Lipase Units/g (LU/g). One LU is the amount of enzyme which releases 1 μmol of butyric acid per minute under the conditions of the assay. 24 To determine the optimum pH, temperature and thermostability profiles of the food enzyme, a different activity assay was used substituting tributyrin by an olive oil emulsion as a substrate and determining the released free fatty acids by a colorimetric reaction. The food enzyme has a temperature optimum around 30°C (pH 6.0) and a pH optimum around pH 7.0 (30°C). Thermostability was tested by pre‐incubation of the food enzyme for 30 min at different temperatures (pH 6.0). Enzyme activity decreased above 60°C showing no residual activity at 80°C. 25 Chemical parameters Data on the chemical parameters of the food enzyme were provided for three batches used for commercialisation and two batches produced for the toxicological tests (Table 1). 26 The mean total organic solids (TOS) of the three food enzyme batches for commercialisation was 15.9% and the mean enzyme activity/TOS ratio was 839 LU/mg TOS. TABLE 1Composition of the food enzyme.ParametersUnitBatches1234 a 5 b Triacylglycerol lipase activity LU/g c 131,000136,000134,000131,00090,600 Protein %10.011.111.3NA d 7.8 Ash %0.30.30.30.30.3 Water %84.183.483.886.287.4 Total organic solids (TOS) e %15.616.315.913.512.3 Triacylglycerol lipase /TOS ratio LU/mg TOS840834843970737 a Batch used for the genotoxicity studies. b Batch used for the repeated dose 90‐day oral toxicity study. c LU: Lipase Units (see Section 3.3.1). d NA: not analysed. e TOS calculated as 100% – % water – % ash. Composition of the food enzyme. Batch used for the genotoxicity studies. Batch used for the repeated dose 90‐day oral toxicity study. LU: Lipase Units (see Section 3.3.1). NA: not analysed. TOS calculated as 100% – % water – % ash. Purity The lead content in all the batches was below 0.5 mg/kg 27 which complies with the specification for lead as laid down in the general specifications for enzymes used in food processing (FAO/WHO, 2006). In addition, arsenic, cadmium and mercury concentrations were below the limits of detection (LoD) of the employed methods in the three commercial batches. 28 , 29 The food enzyme complies with the microbiological criteria for total coliforms, Escherichia coli and Salmonella as laid down in the general specifications for enzymes used in food processing (FAO/WHO, 2006). 30 No antimicrobial activity was detected in any of the tested batches. 31 Strains of Aspergillus species, in common with most filamentous fungi, have the capacity to produce a range of secondary metabolites (Frisvad et al., 2018). The presence of kojic acid, 3‐nitropropionic acid and cyclopiazonic acid was examined in all food enzyme batches, and all were below the LoD of the applied methods. 32 , 33 Adverse effects caused by the potential presence of other secondary metabolites is addressed by the toxicological examination of the food enzyme. The Panel considered that the information provided on the purity of the food enzyme was sufficient. Viable cells and DNA of the production strain The absence of viable cells of the production strain in the food enzyme was demonstrated in three independent liquid batches tested in triplicate. ■■■■■. No colonies were produced. A positive control was included. 34 The absence of recombinant DNA in the food enzyme was demonstrated by PCR analysis of three batches in triplicate. No DNA was detected with primers that would amplify a fragment of ■■■■■ specific for a region containing a deletion in the ■■■■■, with a LoD of 10 ng spiked DNA/g food enzyme. 35 Toxicological data A battery of toxicological tests including a bacterial reverse mutation test (Ames test), an in vitro mammalian cell micronucleus test and a repeated dose 90‐day oral toxicity study in rats has been provided. The batches 4 and 5 (Table 1) used in these studies have similar protein patterns and activity/TOS ratios as the batches intended for commercialisation and thus are considered suitable as test items. Genotoxicity Bacterial reverse mutation test A bacterial reverse mutation test (Ames test) was performed according to the Organisation for Economic Co‐operation and Development (OECD) Test Guideline 471 (OECD, 1997) and following Good Laboratory Practice (GLP). 36 Four strains of Salmonella Typhimurium (TA98, TA100, TA1535 and TA1537) and Escherichia coli WP2uvrA pKM101 were used with or without metabolic activation (S9‐mix), applying the ‘treat and plate’ assay. Four experiments were carried out in triplicate. The first experiment was performed using six concentrations of the food enzyme ranging from 14.47 to 4521 μg TOS/plate. Toxic effects, evident as a reduction in the number of revertant colonies and background bacterial lawn or complete killing of the test bacteria, occurred in TA1535 strain without and with S9‐mix at 1447 and 4521 μg TOS/plate and in TA1537 strain at all concentrations tested with S9‐mix. The second experiment was carried out using six concentrations of the food enzyme ranging from 160 to 5000 μg TOS/plate in all tester strains. Toxic effects, evident as a reduction in background bacterial lawn, occurred in TA1537 strain at all concentrations tested with S9‐mix. The third experiment was performed using TA1537 strain with S9‐mix and six concentrations of the food enzyme ranging from 1.6 to 5000 μg TOS/plate. Toxic effects, evident as a reduction in the number of revertant colonies and background bacterial lawn or complete killing of the test bacteria, occurred at concentrations of 1.6 μg TOS/plate and above. The fourth experiment was carried out using TA1537 strain with S9‐mix and 12 concentrations of the food enzyme ranging from 0.0005 to 160 μg TOS/plate. Toxic effects, evident as a reduction in the number of revertant colonies and background bacterial lawn or complete killing of the test bacteria, occurred at concentrations of 0.16 μg TOS/plate and above. Upon treatment with the food enzyme there was no biologically relevant increase in the number of revertant colonies above the control values, in any strain tested, with or without S9‐mix. The study was considered reliable without restrictions and the results of high relevance. The Panel concluded that the food enzyme triacylglycerol lipase did not induce gene mutations under the test conditions applied in this study. In vitro mammalian cell micronucleus test The in vitro mammalian cell micronucleus test was carried out according to OECD Test Guideline 487 (OECD, 2010) and following GLP. 37 An experiment was performed with duplicate cultures of human peripheral whole blood lymphocytes. The cell cultures were treated with the food enzyme with or without metabolic activation (S9‐mix). Based on the results from range‐finding test, in the main experiment, the cells were exposed to the food enzyme and scored for the frequency of bi‐nucleated cells with micronuclei (MNBN) at concentrations of 905, 2716 and 4527 μg TOS/mL in a short‐term treatment (3‐h exposure and 21‐h recovery period) without S9‐mix, at concentrations of 0.5, 1.8 and 2.7 μg TOS/mL in a short‐term treatment (3‐h exposure and 21‐h recovery period) with S9‐mix and at concentrations of 362, 905 and 1449 μg TOS/mL in a long‐term treatment (24‐h exposure and 24‐h recovery period) without S9‐mix. Cytotoxicity of 31%, 52% and 54% (based on replication index) was observed at the highest concentrations tested in the short‐term with S9‐mix, without S9‐mix and in the long‐term treatment, respectively. The frequency of MNBN was not statistically significantly different to the negative controls at all concentrations tested. The study was considered reliable without restrictions and the results of high relevance. The Panel concluded that the food enzyme triacylglycerol lipase did not induce an increase in the frequency of MNBN under the test conditions applied in this study. Repeated dose 90‐day oral toxicity study in rodents The repeated dose 90‐day oral toxicity study was performed under GLP and according to the OECD Test Guideline 408 (OECD, 2018). 38 Groups of 10 male and 10 female Han Wistar (RccHan™, WIST) rats received the food enzyme by gavage in doses of 128, 423 or 1283 mg TOS/kg body weight (bw) per day. Controls received the vehicle (reverse osmosis water). One mid‐dose male was euthanised in week 7 of administration following misdosing. In the functional observations, a statistically significant decrease in the forelimb grip strength was observed in low‐, mid‐ and high‐dose males (−9%, −10% and −8%). A statistically significant decrease in motor activity, the high beam score at the 6‐min interval in low‐dose males (−26%) and a decrease in the low beam scores at the 6‐min interval in low‐, mid‐ and high‐dose females (−21%, −35%, −17%), at the 24‐min interval in mid‐ and high‐dose females (−39% both), at 30‐min interval in low‐, mid‐ and high‐dose females (−37%, −40%, −54%) and at the 42‐min interval in low‐, mid‐ and high‐dose females (−61%, −73%, −70%) and a decrease in the total low beam score in mid‐ and high‐dose females (−39%, −35%) were reported. The Panel considered the changes as not toxicologically relevant, as they were only recorded at single time intervals (high and low beam scores), they were only observed in one sex (all parameters), there was no dose–response relationship (all parameters, except low beam score at the 30‐min interval) and the changes were within the historical control values (forelimb grip strength, total low beam score). Haematological investigations revealed a statistically significant increase in basophil counts (Bas) in high‐dose males (+67%) and in large unstained cell counts (LUC) in mid‐ and high‐dose males (+125%, +50%). The Panel considered the changes as not toxicologically relevant, as they were only observed in one sex (both parameters), there was no dose–response relationship (LUC) and there were no changes in other relevant parameters (white blood cell count). Clinical chemistry investigations revealed a statistically significant increase in urea (+23%, +21% and +13%), the blood urea nitrogen (BUN;+23%, +21% and +13%) and creatinine (Crea; +20%, +8% and +16%) in low‐, mid‐ and high‐dose males, a decrease in plasma alanine amino‐transferase activity (ALT) in high‐dose males (−37%) and in low‐dose females (−34%), a decrease in plasma albumin (Alb) in mid‐ and high‐dose males (−5%, −3%) and a decrease in potassium concentration (K) in low‐dose females (−11%). The Panel considered the changes as not toxicologically relevant, as they were only observed in one sex (urea, BUN, Crea, Alb, K), there was no dose–response relationship (urea, BUN, Crea, ALT in females, Alb, K), there were no changes in other relevant parameters (for ALT: other liver enzymes, for Alb: total protein or A/G ratio; for K: other electrolytes), there were no histopathological changes in kidneys and liver and the changes were within the historical control values (all parameters). Statistically significant changes in hormone levels included an increase in serum tri‐iodothyronine (T3) in low‐, mid‐ and high‐dose males (+33%, +24%, +28%), an increase in thyroxine (T4) in low‐dose males (+32%) and a decrease in thyroid stimulating hormone (TSH) in mid‐ and high‐dose females (−38%, −43%). The Panel considered the changes as not toxicologically relevant, as they were only observed in one sex (all parameters), there was no dose–response relationship (T3, T4), there were no histopathological changes in thyroid gland and the changes were within the historical control values (all parameters). Statistically significant changes detected in organ weights were a decrease in relative combined prostate/seminal vesicle/coagulating gland weight in mid‐ and high‐dose males (−11%, −13%), an increase in relative liver weight in high‐dose males (+7%) and an increase in relative ovary weight in low‐, mid‐ and high‐dose females (+18%, +18% and +15%). The Panel considered the changes as not toxicologically relevant, as they were only observed in one sex (relative liver weight), there was no dose–response relationship (relative ovary weight), there were no histopathological changes in the relevant organs and the changes were within the historical control values (all parameters). No other statistically significant or toxicologically relevant differences from controls were reported. The Panel identified a no observed adverse effect level (NOAEL) of 1283 mg TOS/kg bw per day, the highest dose tested. Allergenicity The allergenicity assessment considered only the food enzyme and not additives, carriers or other excipients that may be used in the final formulation. The potential allergenicity of the triacylglycerol lipase produced with the A. oryzae strain NZYM‐PH was assessed by comparing its amino acid sequence with those of known allergens as described in the EFSA GMO Scientific Opinion (EFSA GMO Panel, 2010). Using higher than 35% identity in a sliding window of 80 amino acids as the criterion, no match was found in the COMPARE and WHO/IUIS Allergen nomenclature databases. 39 No reports on oral or respiratory sensitisation or elicitation reactions of the triacylglycerol lipase under assessment have been published. 40 Respiratory allergic reactions following occupational inhalation of triacylglycerol lipase have been reported (Brant et al., 2004; Elms et al., 2003; Martel et al., 2010). Several studies have shown that individuals respiratorily sensitised to a food enzyme are usually able to ingest the corresponding enzyme without acquiring clinical symptoms of food allergy (Armentia et al., 2009; Cullinan et al., 1997; Poulsen, 2004). Adverse reactions upon dietary exposure to triacylglycerol lipases in individuals sensitised through the respiratory route have not been reported. The Panel considered that the results of the sequence homology search and the available literature do not indicate a risk of allergic reactions upon dietary exposure to the triacylglycerol lipase under assessment. The production strain belongs to the Aspergillus genus, which is known to cause respiratory allergy (Kurup et al., 2000; Shen & Han, 1998; Vermani et al., 2015). Allergic reactions upon dietary exposure have been observed, but are rare (Xing et al., 2022). The biomass is removed during the production process; however, allergenic proteins of the production strain can be released into the culture medium from which the food enzyme is obtained. ■■■■■, a known source of allergens is present in the culture medium. During the fermentation process, this product will mostly be degraded and utilised by the production strain. Taken together, concerning the potential allergic reactions due to the production strain and the raw material in the culture medium, the Panel considered that residual amounts of allergenic proteins could be present in the food enzyme. Taking into account the level of dietary exposure (see Section 3.5.2), this would result in minute amounts in the final foods, from which allergic reactions are usually not expected. In conclusion, the Panel considered that under the conditions of use, a risk of allergic reactions upon dietary exposure to this food enzyme cannot be excluded, but that the likelihood is low. Dietary exposure Intended use of the food enzyme The food enzyme is intended to be used in six food manufacturing processes at the recommended use levels summarised in Table 2. TABLE 2Intended uses and recommended use levels of the food enzyme as provided by the applicant. 41 Food manufacturing process a Raw material (RM)Maximum recommended use level (mg TOS/kg RM) b , c Processing of dairy products Production of modified milk proteins Milk proteins 35.8 Processing of eggs and egg products Eggs (whole eggs, yolk or white) 42 47.7 Processing of cereals and other grains Production of baked products Flour 14.9 Production of cereal‐based products other than baked Flour 14.9 Processing of plant‐ and fungal‐derived products Production of plant‐based analogues of milk and milk products 43 Cereals, legumes, oilseeds, nuts, etc 14.9 Production of protein hydrolysates from plants and fungi Plant and fungal proteins 35.8 a The name has been harmonised according to the ‘Food manufacturing processes and technical data used in the exposure assessment of food enzymes’ (EFSA CEP Panel, 2023). b Based on 0.839 KLU/mg TOS. c The numbers in bold were used for calculation. Intended uses and recommended use levels of the food enzyme as provided by the applicant. 41 Production of modified milk proteins Production of modified milk proteins Processing of eggs and egg products Processing of eggs and egg products Production of baked products Production of baked products Production of cereal‐based products other than baked Production of cereal‐based products other than baked Production of plant‐based analogues of milk and milk products 43 Production of plant‐based analogues of milk and milk products 43 Production of protein hydrolysates from plants and fungi Production of protein hydrolysates from plants and fungi The name has been harmonised according to the ‘Food manufacturing processes and technical data used in the exposure assessment of food enzymes’ (EFSA CEP Panel, 2023). Based on 0.839 KLU/mg TOS. The numbers in bold were used for calculation. In the production of modified milk proteins and in the production of protein hydrolysates from plants and fungi, the food enzyme is added together with proteolytic enzymes during the hydrolysis step. 44 The enzyme is used to catalyse the hydrolysis of lipids to modify the emulsifying properties. 45 The food enzyme–TOS remain in the final food ingredients. In the processing of eggs and egg products, the food enzyme is added to the whole eggs, egg yolk or egg white 46 prior to pasteurisation. 47 The hydrolysis of phospholipids improves the emulsifying properties. 48 The food enzyme–TOS remain in the final egg products. In the production of baked products, the food enzyme is added to flour during dough making. 49 The triacylglycerol lipase catalyses the hydrolysis of fats and oils in flour to achieve emulsifying effects and enhance dough development. The food enzyme–TOS remain in the baked products. In the production of cereal‐based products other than baked, the triacylglycerol lipase is added to flour during the preparation of the dough. 50 The hydrolysis catalysed by the triacylglycerol lipase reduces batter stiffness, facilitates the handling of dough and improves the dough structure. 51 The food enzyme–TOS remain in the final foods. In the production of plant‐based analogues of milk and milk products, the food enzyme is added to cereals during the saccharification step 52 to hydrolyse acylglycerols. The released medium chain fatty acids improve the taste. The food enzyme–TOS remain in these plant‐based analogues. Based on data provided on thermostability (see Section 3.3.1) and the downstream processing step applied in the respective food manufacturing processes, the Panel considered that this triacylglycerol lipase is inactivated in the majority of the food manufacturing processes listed in Table 2. However, it may remain in its active form in baked products, depending on the heat treatments conditions. Dietary exposure estimation Chronic exposure to the food enzyme–TOS was calculated by combining the maximum recommended use level with individual consumption data (EFSA CEP Panel, 2021). The estimation involved selection of relevant food categories and application of technical conversion factors (EFSA CEP Panel, 2023). Table 3 provides an overview of the derived exposure estimates across all surveys. Detailed mean and 95th percentile exposure to the food enzyme–TOS per age class, country and survey, as well as contribution from each FoodEx category to the total dietary exposure are reported in Appendix A – Tables 1 and 2. For the present assessment, food consumption data were available from 48 dietary surveys (covering infants, toddlers, children, adolescents, adults and the elderly), carried out in 26 European countries (Appendix B). The highest dietary exposure was estimated to be 0.226 mg TOS/kg bw per day in toddlers at the 95th percentile. TABLE 3Summary of the estimated dietary exposure to food enzyme–TOS in six population groups.Population groupEstimated exposure (mg TOS/kg body weight per day)InfantsToddlersChildrenAdolescentsAdultsThe elderly Age range 3–11 months12–35 months3–9 years10–17 years18–64 years≥ 65 years Min–max mean (number of surveys)0.029–0.097 (12)0.060–0.127 (15)0.031–0.111 (19)0.009–0.070 (21)0.020–0.040 (22)0.018–0.040 (23) Min–max 95th percentile (number of surveys)0.082–0.210 (11)0.117–0.226 (14)0.067–0.205 (19)0.021–0.121 (20)0.043–0.083 (22)0.036–0.070 (22) Summary of the estimated dietary exposure to food enzyme–TOS in six population groups. Uncertainty analysis In accordance with the guidance provided in the EFSA opinion related to uncertainties in dietary exposure assessment (EFSA, 2006), the following sources of uncertainties have been considered and are summarised in Table 4. TABLE 4Qualitative evaluation of the influence of uncertainties on the dietary exposure estimate.Sources of uncertaintiesDirection of impact Model input data Consumption data: different methodologies/representativeness/underreporting/misreporting/no portion size standard+/−Use of data from food consumption surveys of a few days to estimate long‐term (chronic) exposure for high percentiles (95th percentile)+Possible national differences in categorisation and classification of food+/− Model assumptions and factors Selection of broad FoodEx categories for the exposure assessment+Exposure to food enzyme–TOS always calculated based on the recommended maximum use level+Use of recipe fractions to disaggregate FoodEx categories+/−Use of technical factors in the exposure model+/− Notes: +, uncertainty with potential to cause overestimation of exposure; –, uncertainty with potential to cause underestimation of exposure. Qualitative evaluation of the influence of uncertainties on the dietary exposure estimate. Notes: +, uncertainty with potential to cause overestimation of exposure; –, uncertainty with potential to cause underestimation of exposure. The conservative approach applied to estimate the dietary exposure to the food enzyme–TOS, in particular assumptions made on the occurrence and use levels of this specific food enzyme, is likely to have led to an overestimation of the exposure. Margin of exposure A comparison of the NOAEL (1283 mg TOS/kg bw per day) identified from the 90‐day rat study with the derived exposure estimates of 0.009–0.127 mg TOS/kg bw per day at the mean and from 0.021 to 0.226 mg TOS/kg bw per day at the 95th percentile resulted in a margin of exposure of at least 5677. CONCLUSIONS Based on the data provided and the derived margin of exposure, the Panel concluded that the food enzyme triacylglycerol lipase produced with the genetically modified Aspergillus oryzae strain NZYM‐PH does not give rise to safety concerns under the intended conditions of use. The Panel considered the food enzyme free from viable cells of the production organism and recombinant DNA. DOCUMENTATION AS PROVIDED TO EFSA Application for authorisation of the food enzyme triacylglycerol lipase from a genetically modified Aspergillus oryzae (strain NZYM‐PH) in accordance with Regulation (EC) No 1331/2008. November 2015. Submitted by Novozymes A/S. Additional information. March 2024. Submitted by Novozymes A/S. ABBREVIATIONS albumin amino‐transferase activity blood urea nitrogen base pair body weight Chemical Abstracts Service EFSA Panel on Food Contact Materials, Enzymes and Processing Aid European Inventory of Existing Commercial Chemical Substances Food and Agricultural Organization of the United Nations EFSA Panel on Food Enzymes 5‐fluoro‐orotic acid good laboratory practice genetically modified microorganism genetically modified organism International Union of Biochemistry and Molecular Biology Joint FAO/WHO Expert Committee on Food Additives kiloDalton kilo lipase units limit of detection large unstained cell counts bi‐nucleated cells with micronuclei margin of exposure no observed adverse effect level Organisation for Economic Co‐operation and Development polymerase chain reaction raw material real‐time polymerase chain reaction total organic solids World Health Organization REQUESTOR European Commission QUESTION NUMBER EFSA‐Q‐2015‐00664 COPYRIGHT FOR NON‐EFSA CONTENT EFSA may include images or other content for which it does not hold copyright. In such cases, EFSA indicates the copyright holder and users should seek permission to reproduce the content from the original source. PANEL MEMBERS José Manuel Barat Baviera, Claudia Bolognesi, Francesco Catania, Gabriele Gadermaier, Ralf Greiner, Baltasar Mayo, Alicja Mortensen, Yrjö Henrik Roos, Marize de Lourdes Marzo Solano, Henk Van Loveren, Laurence Vernis, and Holger Zorn. NOTE The full opinion will be published in accordance with Article 12 of Regulation (EC) No 1331/2008 once the decision on confidentiality will be received from the European Commission. Supporting information APPENDIX A: Dietary exposure estimates to the food enzyme–TOS in details